Acorda Therapeutics has filed for bankruptcy protection, hoping to keep operating while it tries to arrange the sale of its main assets to a US subsidiary of Germany’s Mer
UK company Redx Pharma has decided it would be better off in private hands than publicly listed on the Alternative Investment Market (AIM), and has started the process of
Bayer chief executive Bill Anderson pulled no punches in his assessment of the company at its annual results update, saying it is “badly broken” by patent losses, litigati
Stellar results in a bladder cancer study have prompted Astellas to raise its peak sales prediction for Pfizer-partnered antibody-drug conjugate Padcev, although its new m
Better-than-expected sales of some of its new products, including Skyrizi and Rinvoq, helped AbbVie handle a sharp decline in sales of former cash-cow product Humira in th
GSK and Pfizer’s full-year financial results show that the former is currently winning the battle for take-up of their rival respiratory syncytial virus (RSV) vaccines, al